BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Lung cancer AND LRP1B, ENSG00000168702, 53353, Q9NZR2, LRPDIT, LRP-DIT AND Treatment
18 results:

  • 1. Comprehensive genomic profiling of pulmonary spindle cell carcinoma using tissue and plasma samples: insights from a real-world cohort analysis.
    Sun Y; Qin S; Wang S; Pang J; Ou Q; Liang W; Zhong H
    J Pathol Clin Res; 2024 May; 10(3):e12375. PubMed ID: 38661052
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Multi-omics Analysis Reveals Immune Features Associated with Immunotherapy Benefit in Patients with Squamous Cell lung cancer from Phase III lung-MAP S1400I Trial.
    Parra ER; Zhang J; Duose DY; Gonzalez-Kozlova E; Redman MW; Chen H; Manyam GC; Kumar G; Zhang J; Song X; Lazcano R; Marques-Piubelli ML; Laberiano-Fernandez C; Rojas F; Zhang B; Taing L; Jhaveri A; Geisberg J; Altreuter J; Michor F; Provencher J; Yu J; Cerami E; Moravec R; Kannan K; Luthra R; Alatrash G; Huang HH; Xie H; Patel M; Nie K; Harris J; Argueta K; Lindsay J; Biswas R; Van Nostrand S; Kim-Schulze S; Gray JE; Herbst RS; Wistuba II; Gettinger S; Kelly K; Bazhenova L; Gnjatic S; Lee JJ; Zhang J; Haymaker C
    Clin Cancer Res; 2024 Apr; 30(8):1655-1668. PubMed ID: 38277235
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Screening of novel tumor-associated antigens for lung adenocarcinoma mRNA vaccine development based on pyroptosis phenotype genes.
    Zhou F; Wang M; Wang Z; Li W; Lu X
    BMC Cancer; 2024 Jan; 24(1):28. PubMed ID: 38166691
    [TBL] [Abstract] [Full Text] [Related]  

  • 4.
    Feng H; Xu H; Shi X; Ding G; Yan C; Li L; Jian Z; Yang X; Guo H; Li F; Zhang J; Ren X
    Front Biosci (Landmark Ed); 2023 Jul; 28(7):147. PubMed ID: 37525904
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Molecular profiling and prognostic biomarkers in chinese non-small cell lung cancer cohort.
    Shen F; Guo W; Song X; Wang B
    Diagn Pathol; 2023 Jun; 18(1):71. PubMed ID: 37301854
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Spatial profiling of the microenvironment reveals low intratumoral heterogeneity and STK11-associated immune evasion in therapy-naïve lung adenocarcinomas.
    Goldschmid H; Kluck K; Ball M; Kirchner M; Allgäuer M; Winter H; Herth F; Heußel CP; Pullamsetti SS; Savai R; Yong TTK; Schirmacher P; Peters S; Thomas M; Christopoulos P; Budczies J; Stenzinger A; Kazdal D
    Lung Cancer; 2023 Jun; 180():107212. PubMed ID: 37141769
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Promising efficacy of immune checkpoint inhibitor plus chemotherapy for thoracic SMARCA4-deficient undifferentiated tumor.
    Lin Y; Yu B; Sun H; Zhang H; Hu Z; Zhang Y; Wu Z; Sun S; Zhao X; Yu H; Wu X; Li Y; Wang J; Wang H
    J Cancer Res Clin Oncol; 2023 Sep; 149(11):8663-8671. PubMed ID: 37115272
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Genomic Characteristics and the Potential Clinical Implications in Oligometastatic Non-Small Cell lung cancer.
    Liao R; Chen K; Li J; He H; Yi G; Huang M; Chen R; Shen L; Zhang X; Xu Z; Yang Z; Peng Y
    Cancer Res Treat; 2023 Jul; 55(3):814-831. PubMed ID: 36634615
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Increased blood-based intratumor heterogeneity (bITH) is associated with unfavorable outcomes of immune checkpoint inhibitors plus chemotherapy in non-small cell lung cancer.
    Zhou J; Bao M; Gao G; Cai Y; Wu L; Lei L; Zhao J; Ji X; Huang Y; Su C
    BMC Med; 2022 Jul; 20(1):256. PubMed ID: 35902848
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Molecular and Clinicopathological Characteristics of lung cancer Concomitant Chronic Obstructive Pulmonary Disease (COPD).
    Ma H; Zhang Q; Zhao Y; Zhang Y; Zhang J; Chen G; Tan Y; Zhang Q; Duan Q; Sun T; Qi C; Li F
    Int J Chron Obstruct Pulmon Dis; 2022; 17():1601-1612. PubMed ID: 35860812
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. PAPPA2 mutation as a novel indicator stratifying beneficiaries of immune checkpoint inhibitors in skin cutaneous melanoma and non-small cell lung cancer.
    Dong Y; Zhao L; Duan J; Bai H; Chen D; Li S; Yu Y; Xiao M; Zhang Q; Duan Q; Sun T; Qi C; Wang J; Wang Z
    Cell Prolif; 2022 Sep; 55(9):e13283. PubMed ID: 35811392
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Co-Mutation of FAT3 and lrp1b in lung Adenocarcinoma Defines a Unique Subset Correlated With the Efficacy of Immunotherapy.
    Zhu M; Zhang L; Cui H; Zhao Q; Wang H; Zhai B; Jiang R; Jiang Z
    Front Immunol; 2021; 12():800951. PubMed ID: 35069585
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. [Analysis of the feasibility and prognostic value of circulating tumor DNA in detecting gene mutations in small cell lung cancer].
    Jin Y; Chen YM; Hu X; Tang HR; Yu XM; Fan Y; Xu YJ; Xu HM; Li PS; Li Q; Chang LP; Guan YF; Chen M
    Zhonghua Yi Xue Za Zhi; 2020 Dec; 100(45):3614-3621. PubMed ID: 33333686
    [No Abstract]    [Full Text] [Related]  

  • 14. Comprehensive genomic profile of Chinese lung cancer patients and mutation characteristics of individuals resistant to icotinib/gefitinib.
    Shang Y; Li X; Liu W; Shi X; Yuan S; Huo R; Fang G; Han X; Zhang J; Wang K; Dou Z; Zhang Y; Zang A; Zhang L
    Sci Rep; 2020 Nov; 10(1):20243. PubMed ID: 33219256
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Association of clinico-genomic characteristics with tumor mutational burden in small cell lung cancer patients.
    Kachroo S; Shao C; Desai K; He J; Jin F; Sen S
    Future Oncol; 2021 Feb; 17(4):423-433. PubMed ID: 33198513
    [No Abstract]    [Full Text] [Related]  

  • 16. The combination of camrelizumab and apatinib obtained ongoing partial remission for a patient with osimertinib-resistant non-small cell lung cancer: case report.
    Cong X; Chen J; Zheng W
    Ann Palliat Med; 2021 Mar; 10(3):3469-3474. PubMed ID: 33040541
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Genomic analysis of oesophageal squamous-cell carcinoma identifies alcohol drinking-related mutation signature and genomic alterations.
    Chang J; Tan W; Ling Z; Xi R; Shao M; Chen M; Luo Y; Zhao Y; Liu Y; Huang X; Xia Y; Hu J; Parker JS; Marron D; Cui Q; Peng L; Chu J; Li H; Du Z; Han Y; Tan W; Liu Z; Zhan Q; Li Y; Mao W; Wu C; Lin D
    Nat Commun; 2017 May; 8():15290. PubMed ID: 28548104
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Somatic mutations affect key pathways in lung adenocarcinoma.
    Ding L; Getz G; Wheeler DA; Mardis ER; McLellan MD; Cibulskis K; Sougnez C; Greulich H; Muzny DM; Morgan MB; Fulton L; Fulton RS; Zhang Q; Wendl MC; Lawrence MS; Larson DE; Chen K; Dooling DJ; Sabo A; Hawes AC; Shen H; Jhangiani SN; Lewis LR; Hall O; Zhu Y; Mathew T; Ren Y; Yao J; Scherer SE; Clerc K; Metcalf GA; Ng B; Milosavljevic A; Gonzalez-Garay ML; Osborne JR; Meyer R; Shi X; Tang Y; Koboldt DC; Lin L; Abbott R; Miner TL; Pohl C; Fewell G; Haipek C; Schmidt H; Dunford-Shore BH; Kraja A; Crosby SD; Sawyer CS; Vickery T; Sander S; Robinson J; Winckler W; Baldwin J; Chirieac LR; Dutt A; Fennell T; Hanna M; Johnson BE; Onofrio RC; Thomas RK; Tonon G; Weir BA; Zhao X; Ziaugra L; Zody MC; Giordano T; Orringer MB; Roth JA; Spitz MR; Wistuba II; Ozenberger B; Good PJ; Chang AC; Beer DG; Watson MA; Ladanyi M; Broderick S; Yoshizawa A; Travis WD; Pao W; Province MA; Weinstock GM; Varmus HE; Gabriel SB; Lander ES; Gibbs RA; Meyerson M; Wilson RK
    Nature; 2008 Oct; 455(7216):1069-75. PubMed ID: 18948947
    [TBL] [Abstract] [Full Text] [Related]  


    of 1.